Quadrant Capital Group LLC Purchases 3,267 Shares of Medtronic PLC $MDT

Quadrant Capital Group LLC lifted its holdings in Medtronic PLC (NYSE:MDT) by 27.4% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,185 shares of the medical technology company’s stock after purchasing an additional 3,267 shares during the period. Quadrant Capital Group LLC’s holdings in Medtronic were worth $1,324,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Gilbert & Cook Inc. raised its position in Medtronic by 1.9% in the second quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock worth $532,000 after acquiring an additional 114 shares during the period. Red Spruce Capital LLC raised its holdings in Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock worth $2,067,000 after purchasing an additional 118 shares during the period. Certior Financial Group LLC lifted its position in Medtronic by 3.7% during the first quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after purchasing an additional 122 shares in the last quarter. PrairieView Partners LLC grew its holdings in Medtronic by 3.6% during the second quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock valued at $324,000 after purchasing an additional 128 shares during the period. Finally, Baker Avenue Asset Management LP grew its holdings in Medtronic by 3.1% during the first quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company’s stock valued at $410,000 after purchasing an additional 136 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Activity

In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is owned by company insiders.

Medtronic Stock Down 0.5%

Shares of MDT stock opened at $104.53 on Friday. The company’s fifty day simple moving average is $96.06 and its two-hundred day simple moving average is $91.66. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $106.33. The stock has a market cap of $134.00 billion, a P/E ratio of 28.79, a PEG ratio of 2.42 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business’s revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on MDT. Robert W. Baird lifted their price objective on Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Morgan Stanley lifted their price target on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Friday, November 14th. Finally, Barclays upped their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, November 20th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $110.44.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.